Company intelligence
Novo Nordisk
We’re here to champion long-term health. Get updates on innovation and inspiring stories 💙
About Novo Nordisk
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ about 66,700 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
Verified activity
Signals from Novo Nordisk
36 published signals
People
Novo Nordisk is hiring Sara Gullestrup Marcussen as a team member
Reported by John Kuckelman
Presence & Recognition
Novo Nordisk player Katarína Frost Nielsen reached the Top 1% of all players
Reported by Katarína Frost Nielsen
Research & Knowledge
Novo Nordisk published results from a large late-stage clinical trial showing that 40.4% of children moved from the obesity BMI category to the overweight or even healthy-weight category.
Reported by Novo Nordisk
People
Novo Nordisk employee Iria Gala is leaving the company and starting a new chapter.
Reported by Iria Gala
People
Novo Nordisk completed the EMERGE talent development program over the past two months, involving team members, coaches, and course lead Kenneth Overgaard Ege.
Reported by Marc Ryning
Research & Knowledge
Novo Nordisk published a study in which oxytocin failed to reduce food intake or appetite in people with obesity.
Reported by Filip K. Knop
Research & Knowledge
Novo Nordisk colleagues from the Center for Clinical Metabolic Research tested a crossover study in which participants received 2 doses of intravenous oxytocin or placebo while glucose was increased stepwise over 3 hours.
Reported by Filip K. Knop
Presence & Recognition
Novo Nordisk participated in the global development program in Denmark called BOOST for upcoming leaders in Legal, IP & Security, featuring 30 profiles from across the world.
Reported by Thomas Rask Nielsen
Research & Knowledge
Novo Nordisk completed enrollment in a clinical trial dedicated to individuals living with a rare disease.
Reported by Giuseppe Panio
People
Novo Nordisk is hiring a Process Orchestration Leader to drive stronger end-to-end processes, collaboration, and impact.
Reported by Mette Thomsen
People
Novo Nordisk announced that it is part of a leadership team where teams and functions come together as OneTeamSwitzerland.
Reported by Vanessa Ilg-Schlinkmann
Presence & Recognition
Novo Nordisk is participating in a panel event at DPHARM with colleagues across industry.
Reported by Candice Fitzgerald
Presence & Recognition
Novo Nordisk hosted the 6th Annual Summer Games to support and raise funds for Special Olympics New Jersey, with over 500 teammates participating.
Reported by Steven Benz
Presence & Recognition
Novo Nordisk has been a main partner of Climbing for Life for many years.
Reported by De Muyt Axel
People
Novo Nordisk is seeking a Pricing and Policy Insights Manager to shape strategic decisions across the business.
Reported by Erin Pensalfini
People
Novo Nordisk is hiring a Vice President, Payer Strategy & Pricing to join the leadership team.
Reported by Tom Scales
People
Novo Nordisk is hiring a Director of Clinical Development to take ownership in execution and monitoring of clinical trials, ideally Phase 3, with a fully remote position in the US.
Reported by James Cartier
People
Novo Nordisk is hiring for a Senior Director of Sickle Cell Field Sales within the Rare Disease team.
Reported by Colleen Silk
Presence & Recognition
Novo Nordisk is committed to driving change to defeat serious chronic diseases.
Reported by Muriel De Vos
People
Novo Nordisk is hiring a Category Management Manager - Clinical Services for strategic sourcing initiatives and procurement category management.
Reported by Erin Pensalfini
Research & Knowledge
Novo Nordisk published a manuscript titled Method Matters on extracellular vesicles supervised by Dres Damgaard.
Reported by Dres Damgaard
Presence & Recognition
Novo Nordisk preliminary data from the next phase of the work has been selected for an oral presentation at ISEVxTech 2026 in November.
Reported by Dres Damgaard
Research & Knowledge
Novo Nordisk is building the biggest cardiometabolic clinical trial data foundation in the world, with over 200,000 patient-years of data and counting.
Reported by Siddhant Prabhu
People
Novo Nordisk officially kicked off the IO Finance Graduate Programme with Melanie Knauf starting her first rotation in the EUCAN Business Finance team.
Reported by Melanie Knauf